An observational study of initial HIV RNA decay following initiation of combination antiretroviral treatment during pregnancy

Table 2 Linear regression analysis investigating factors associated with first-phase HIV RNA half-life decay

	Univariate analysis		Multivariate analysis
	Change (95% CI)^a	p-value	Change (95% CI)^a	p-value
Maternal age, per 1-year higher	0.02 (− 0.01, 0.05)	0.24
Black African/Caribbean ethnicity	− 0.13 (− 0.61, 0.35)	0.17
HIV acquired via heterosexual intercourse	1.08 (− 0.34, 2.51)	0.14
Previous cART use	− 0.08 (− 0.45, 0.29)	0.67
Baseline CD4⁺ T-cell count, per 10 cells/µL increase	0.01 (0.00, 0.02)	0.003	0.00 (− 0.01, 0.01)	0.47
Baseline plasma HIV RNA, per 1 log₁₀ copies/mL higher	− 0.71 (− 0.97, − 0.46)	< 0.001	− 0.611 (− 0.918, − 0.305)	< 0.001
Gestational age when cART was started, per 1-week higher	− 0.02 (− 0.05, 0.01)	0.21
Antiretroviral third agent class
PI	0.34 (− 0.04, 0.72)	0.08
NNRTI	− 0.27 (− 0.74, 0.21)	0.27
INSTI	− 0.84 (− 1.46, − 0.23)	0.007	− 0.365 (− 0.982, 0.251)	0.24

CI confidence interval, cART combination antiretroviral treatment, PI protease inhibitor, NNRTI non-nucleoside reverse transcriptase inhibitor, INSTI integrase strand transferase inhibitor
^aChange (95% CI) reflects the associated impact of each independent variable in the model on the first-phase HIV RNA half-life decay

ISSN: 1742-6405